Citation

Pinto JV, Medeiros LS, da Rosa GS, de Oliveira CES, de Souza Crippa JA, Passos IC, Kauer-Sant'Anna M. Neurosci. Biobehav. Rev. 2019; 101: 78-84.

Affiliation

Laboratory of Molecular Psychiatry, Hospital de Clínicas de Porto Alegre, Brazil; Department of Psychiatry, Federal University of Rio Grande do Sul, Brazil. Electronic address: mksantanna@gmail.com.

Copyright

(Copyright © 2019, Elsevier Publishing)

DOI

10.1016/j.neubiorev.2019.04.004

PMID

30974123

Abstract

Bipolar disorder (BD) is commonly associated with comorbidities, especially substance use disorders. In light of this, the present review aimed to investigate the prevalence and clinical correlates of cannabis use in BD. Studies evaluating the prevalence of cannabis use among patients with BD and studies reporting a dichotomous sample of patients with cannabis use compared to those without the use were included. Meta-analyses using random-effects models were performed, and sources of heterogeneity were explored using meta-regression. The search resulted in 2918 publications, of which 53 were included. The prevalence of cannabis use was 24% (95%CI:18-29; k = 35; n = 51,756). Cannabis use was significantly associated with being younger, male, and single; having fewer years of education and an earlier onset of affective symptoms; and lifetime psychotic symptoms, suicide attempts, and use of tobacco, alcohol, and other substances. In conclusion, cannabis use present in almost one-quarter of patients with BD and is associated with factors that are highly relevant for both clinical practice and public health.

Copyright © 2019. Published by Elsevier Ltd.

Language: en

Keywords

Bipolar disorder; cannabis; meta-analysis; meta-regression; psychosis; substance use disorder; suicide